Specialty chemicals company Nouryon says it plans to invest in its Kromasil manufacturing facility in Bohus, Sweden, to meet increasing global demand from the pharmaceutical and biotechnology industries. The investment is expected to double the facility’s existing production capacity, which will strengthen Nouryon’s global position in high-performance silica, according to the company.
Kromasil products are used by the pharmaceutical, food and beverage, clinical and environmental industries for applications ranging from laboratory analysis to industrial-scale purification. Kromasil contributes to improved treatment of diabetes as a vital part of the purification of insulin, according to Nouryon. Other uses include complex bio-pharma applications.
“Bio-pharmaceuticals, such as peptides, proteins and hormones, are a growing market and we see an increase in demand worldwide, particularly from our customers in India, China and Southeast Asia,” says Patrick Wilhelm, vice president of inorganic specialties at Nouryon.
Construction of the Nouryon facility expansion is scheduled to begin in 2022.
For more information, visit: www.nouryon.com